A blood sample could one day be enough to diagnose many types of solid cancers, or to monitor the amount of cancer in a patient’s body and responses to treatment.
Previous versions of the approach, which relies on monitoring levels of tumor DNA circulating in the blood, have required cumbersome and time-consuming steps to customize it to each patient or have not been sufficiently sensitive.
Now, researchers at the Stanford University School of Medicine have devised a way to quickly bring the technique to the clinic. Their approach, which should be broadly applicable to many types of cancers, is highly sensitive and specific. With it they were able to accurately identify about 50 percent of people in the study with stage-1 lung cancer and all patients whose cancers were more advanced.
“We set out to develop a method that overcomes two major hurdles in the circulating tumor DNA field,” said Maximilian Diehn, MD, PhD, the CRK Faculty Scholar and assistant professor of radiation oncology. “First, the technique needs to be very sensitive to detect the very small amounts of tumor DNA present in the blood. Second, to be clinically useful it’s necessary to have a test that works off the shelf for the majority of patients with a given cancer.”
The researchers describe their findings in a paper published online April 6 in Nature Medicine. Diehn shares senior authorship with Ash Alizadeh, MD, PhD, assistant professor of medicine. Postdoctoral scholars Aaron Newman, PhD, and Scott Bratman, MD, PhD share lead authorship.
“We’re trying to develop a general method to detect and measure disease burden,” said Alizadeh, a hematologist and oncologist. “Blood cancers like leukemias can be easier to monitor than solid tumors through ease of access to the blood. By developing a general method for monitoring circulating tumor DNA, we’re in effect trying to transform solid tumors into liquid tumors that can be detected and tracked more easily.”
Even in the absence of treatment, cancer cells are continuously dividing and dying. As they die, they release DNA into the bloodstream, like tiny genetic messages in a bottle. Learning to read these messages — and to pick out the one in 1,000 or 10,000 that come from a cancer cell — can allow clinicians to quickly and noninvasively monitor the volume of tumor, a patient’s response to therapy and even how the tumor mutations evolve over time in the face of treatment or other selective pressures.
“The vast majority of circulating DNA is from normal, non-cancerous cells, even in patients with advanced cancer,” Bratman said. “We needed a comprehensive strategy for isolating the circulating DNA from blood and detecting the rare, cancer-associated mutations. To boost the sensitivity of the technique, we optimized methods for extracting, processing and analyzing the DNA.
The researchers’ technique, which they have dubbed CAPP-Seq, for Cancer Personalized Profiling by deep Sequencing, is sensitive enough to detect just one molecule of tumor DNA in a sea of 10,000 healthy DNA molecules in the blood. Although the researchers focused on patients with non-small-cell lung cancer (which includes most lung cancers, including adenocarcinomas, squamous cell carcinoma and large cell carcinoma), the approach should be widely applicable to many different solid tumors throughout the body. It’s also possible that it could one day be used not just to track the progress of a previously diagnosed patient, but also to screen healthy or at-risk populations for signs of trouble.
Tumor DNA differs from normal DNA by virtue of mutations in the nucleotide sequence. Some of the mutations are thought to be cancer drivers, responsible for initiating the uncontrolled cell growth that is the hallmark of the disease. Others accumulate randomly during repeated cell division. These secondary mutations can sometimes confer resistance to therapy; even a few tumor cells with these types of mutations can expand rapidly in the face of seemingly successful treatment.
Different from patient to patient
“Cancer is a genetic disease,” Alizadeh said. “But unlike Down syndrome, for example, which has a single dominant cause, for most cancers it’s very difficult to identify any one particular genetic aberration or mutation that is found in every patient. Instead, each cancer tends to be genetically different from patient to patient, although sets of mutations can be shared among patients with a given cancer.”
The Latest on: Cancer blood test
via Google News
The Latest on: Cancer blood test
- Blood cells could serve as a 'thermometer' to detect breast canceron May 13, 2020 at 5:04 am
Immune system cells in the blood of breast cancer patients undergo alterations early in the disease course, according to a study published in the journal Clinical & Translational Immunology. The ...
- Parents spot baby's eye cancer in unusual looking picture taken with a flashon May 13, 2020 at 3:24 am
The parents of a baby girl who lost an eye after they spotted and unusual white glow on flash photo have shared their joy after their daughter celebrated her first birthday. Dela-Rose Denham was just ...
- Does Insulin Resistance Worsen Breast Cancer Prognosis in Black Women?on May 12, 2020 at 2:53 pm
Insulin resistance was one factor that mediated invasive breast cancer prognosis among black women, researchers reported. In a cross-sectional study of 115 women newly diagnosed with invasive breast ...
- Blood test seems an effective aid in cancer screeningon May 7, 2020 at 5:05 pm
NEW YORK (Reuters Health) - A multicancer blood test appears to have met its initial goal of being an effective addition to standard screening for cancer, in a study of nearly 10,000 women. The aim of ...
- Blood Test Promising as Colorectal Cancer Screenon May 7, 2020 at 10:36 am
Testing blood for three distinct colorectal cancer (CRC) markers showed perfect sensitivity and 90% specificity for detecting malignancy in a preliminary study, researchers said. The test involves ...
- Grail's 4th funding round nets $390M for its cancer-seeking blood teston May 7, 2020 at 4:30 am
Grail has secured its fourth nine-digit-plus financing round, bringing its total funding to nearly $2 billion as it looks to complete the clinical testing of its cancer-seeking blood test.
- Simple blood test could identify people at greater risk of developing cancer by detecting whether they have abnormally small red blood cellson May 6, 2020 at 3:20 pm
Studying anonymised patient records, UK researchers found that having abnormally small red blood cells appeared to double the risk of developing cancer within the next year.
- Blood test helps detect cancer before symptoms, study findson May 4, 2020 at 11:30 pm
For the first time, a blood test has been shown to help detect many types of cancer in a study of thousands of people with no history or symptoms of ...
- HEALTH: Blood test helped detect cancer before symptoms, study findson May 4, 2020 at 9:15 pm
For the first time, a blood test has been shown to help detect many types of cancer in a study of thousands of people with no history or symptoms of the ...
- Johns Hopkins University develops experimental blood test to fight against breast canceron April 30, 2020 at 2:21 pm
A big step forward in the fight against cancer has been made after Johns Hopkins University developed an experimental blood test that detects several forms of the disease.
via Bing News